Does Rallies show 13F holders for OLMA?

Yes. Rallies tracks hedge fund and 13F ownership data for OLMA, including fund names, share counts, latest tracked quarter, and position changes when available.

Is OLMA research on Rallies investment advice?

No. Rallies provides research, data, and educational context for OLMA. It does not provide personalized investment advice.

OLMA (Olema Pharmaceuticals, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Olema Pharmaceuticals, Inc. Common Stock (OLMA) is a publicly traded Healthcare sector company. As of May 21, 2026, OLMA trades at $13.98 with a market cap of $1.13B and a P/E ratio of -7.24. OLMA moved +6.72% today. Year to date, OLMA is -44.38%; over the trailing twelve months it is +174.80%. Its 52-week range spans $2.86 to $36.26. Analyst consensus is strong buy with an average price target of $39.75. Rallies surfaces OLMA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns OLMA stock?

Hedge funds tracked by Rallies that own OLMA include Duquesne Family and Polen Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Olema Pharmaceuticals, Inc. Common Stock.

OLMA Key Metrics

Key financial metrics for OLMA
Metric	Value
Price	$13.98
Market Cap	$1.13B
P/E Ratio	-7.24
EPS	$-1.87
Dividend Yield	0.00%
52-Week High	$36.26
52-Week Low	$2.86
Volume	11.15K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-162.45M
Gross Margin	0.00%

Top Hedge Funds Holding OLMA

Duquesne Family holds 986.83K shares of OLMA, changed +0.00% as of Mar 31, 2026.
Polen Capital holds 15.21K shares of OLMA, changed +0.00% as of Dec 31, 2025.

Latest OLMA News

Olema Oncology Ends Q1 with $505M Cash, $53M Loss; OPERA-01 Data Fall — May 12, 2026
Olema to Present Phase 1 OP-3136 Data and OPERA-02 Poster at ASCO — Apr 21, 2026
Olema Oncology reveals NCoR1-driven ER antagonism by palazestrant and OP-3136 synergy — Apr 17, 2026
Olema Oncology to Present Two Preclinical Posters on Palazestrant and OP-3136 — Mar 17, 2026
Olema Oncology Raises $218.5M and Advances Phase 3 Palazestrant Trials — Mar 16, 2026

Recent OLMA Insider Trades

Mitchell Shawnte sold 24.77K (~$600.60K) on Mar 4, 2026.
Mitchell Shawnte sold 233 (~$5.75K) on Mar 4, 2026.
Mitchell Shawnte sold 15.00K (~$345.15K) on Mar 3, 2026.

OLMA Analyst Consensus

11 analysts cover OLMA: 0 strong buy, 10 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $39.75.

Common questions about OLMA

Who owns OLMA stock?: Hedge funds tracked by Rallies that own OLMA include Duquesne Family and Polen Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Olema Pharmaceuticals, Inc. Common Stock.
Does Rallies show 13F holders for OLMA?: Yes. Rallies tracks hedge fund and 13F ownership data for OLMA, including fund names, share counts, latest tracked quarter, and position changes when available.
Is OLMA research on Rallies investment advice?: No. Rallies provides research, data, and educational context for OLMA. It does not provide personalized investment advice.